In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
A new annual list will name 100 Latino and Hispanic leaders shaping cannabis around the…
Cannabis technology has come a long way from rolling papers and hand-packed bowls. Edibles, vapes,…
The government spent most of its final brief making the legal case for Schedule III.…
Barney’s Farm pairs eight familiar cannabis names with BF Super Auto #1 to deliver faster,…
Barcelona’s Plan Druida expands police presence and surveillance in response to drug trafficking and use,…
4,516 people logged what they drank for three weeks. On the days they had a…